OXFORD, United Kingdom--(BUSINESS WIRE)--Summit Corporation plc (“Summit”) today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed public offering of American Depositary Shares (“ADSs”). Summit also has applied to have its ADSs listed on the NASDAQ Global Market under the ticker symbol “SMMT”. Following completion of the offering of the ADSs, Summit ordinary shares will continue to be admitted to trading on the AIM market of the London Stock Exchange. The number of ADSs to be offered and the price per ADS for the offering have not been determined.
JMP Securities LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering, with Needham & Company, LLC acting as the lead manager.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from JMP Securities LLC, Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, telephone: +1 (415) 835-8985; from Oppenheimer & Co. Inc., Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, telephone: +1 (212) 667-8563 and from Needham & Company, LLC, Prospectus Department, 445 Park Avenue, 4th floor, New York, NY 10022, telephone: +1 (800) 903-3268.
About Summit
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection. Summit’s principal offices are located in Oxfordshire, U.K., and it has a U.S. office in Cambridge, Massachusetts. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.
Contacts
For Summit
UK office
Glyn Edwards / Richard Pye, +44 (0)1235 443 951
or
US office
Erik Ostrowski, +1 617 294 6607
Help employers find you! Check out all the jobs and post your resume.
